travel tech

B2B travel company grows its Houston presence

Real-time inventory software enables travelers to book a last minute flight and have their boarding passes in hand at security a few minutes later. But that technology isn't utilized in other aspects of a vacation — tour companies, for example. That's where San Francisco-based Xola comes in.

Scott Zimmerman and his co-founder Anush Ramani realized real-time technology was a glaring hole in a multi-billion-dollar business. It's why they founded Xola, a booking and marketing software system designed for tour and activity companies.

"So many smaller tour companies operate with pen and paper," Zimmerman explained. "And for many cities and countries, tourism is the number-two or number-three industry — it's a huge driver of economic growth. It's a $120 billion global market."

They created Xola as a B2B solution that created a platform for operators to promote their offerings, and allow customers to purchase tours and activities. Meanwhile, Xola's custom-design software platform managed the tour inventory and payments, providing real-time inventory management.

Since its inception in 2011, Xola has emerged as a leading B2B solution for travel industry operators. The company started in San Francisco, but opened an office in Houston in 2016 in the Heights Clock Tower. Xola's Houston operation began with six people; today, it employs 17. Zimmerman says he sees potential to grow the team with additional marketing, sales, and support staff.

"We serve customers around the world, and Houston has everything we need to continue our growth."

Zimmerman acknowledged the cost of doing business in the Bay Area is expensive, but when he went looking for cities in which to expand, price wasn't his only concern.

"We wanted a large metropolitan area, with a diverse ecosystem, good universities, a great talent pool, a high quality of life and an affordable cost of living. Houston has all these things. And the more I get to know the city, I realize just how much it has going on."

Zimmerman said that the city has "totally exceeded" his expectations in terms of Xola's growth. He said every one of the Houston employees is wonderful to work with, and loves that they come from diverse cultural and educational backgrounds.

"I can't quite describe what the office is like, but there's a great energy and enthusiasm. [The team] easy to work with. It's been fun in that regard."

Zimmerman said that Houston's talent pool is so extensive, he can't imagine "ever exhausting" the city's resources. He also sees Houston as an asset for Xola's continued growth. The company currently has offices in San Francisco, Houston, Bangalore, and Belgrade and anticipates more expansion in the coming years. Xola's ticketing and software system has received multiple five-star reviews from its customers, who praise not only its ease of operation, but also the company's stellar customer service. In fact, Xola just won a 2018 Ease of Use Award from Capterra.

"In addition to Xola's core booking system, we're building next-generation automated marketing features that help our customers maintain a competitive edge. And our Houston team will continue to grow as we do, so we can continue to serve markets around the world."

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News